VivoSeq
Other

Withdrawal

1

Pipeline Programs↗

4

Active Trials↗

7

Companies Involved↗

Withdrawal is an early-stage landscape with 1 program across 7 companies. The most active players are Eli Lilly, Pfizer, Novartis. 1 program is in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

21/100

Pipeline Velocity

6/100

Mech. Concentration

100/100

Completion Rate

86/100

Attrition Rate

11/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Eli Lilly logo

Eli Lilly

1 program

Phase 3Pfizer logo

Pfizer

0 programs

PreclinicalNovartis logo

Novartis

0 programs

PreclinicalNeurocrine Biosciences logo

Neurocrine Biosciences

0 programs

PreclinicalR

Rare Thyroid Therapeutics International AB

0 programs

PreclinicalAstellas logo

Astellas

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 2
No programs
Phase 31

Nabilone

Bausch Health Americas, Inc.

Approved
No programs

Analysis

Trial Status

71

clinical trials

Completed50 · 70%
Unknown status9 · 13%
Terminated6 · 8%
Recruiting3 · 4%
Withdrawn2 · 3%
Not yet recruiting1 · 1%

Clinical Trials

Trial Activity

71 trials

Effects of Intranasal Oxytocin in the Treatment of Benzodiazepine Withdrawal: A Pilot RCT
Recruiting·SSt. Olavs Hospital·Phase 2·NCT06757517·60 enrolled
Medication Withdrawal in Stable HF With Improved LVEF
Recruiting·HHospital de Clinicas de Porto Alegre·Phase 2/3·NCT07489547·90 enrolled
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo and Active-Controlled Clinical Trial of Titrating Doses of PP-01 for the Mitigation of Cannabis Withdrawal Symptoms in Adults With Cannabis Use Disorder: Core Study With Safety Extension Phase
Recruiting·PPleoPharma, Inc.·Phase 3·NCT07644052·420 enrolled
Pegylated Interferon Alfa-2b in Reducing Relapse Rates After Nucleos(t)ide Analogue Withdrawal in HBeAg-negative CHB Patients with Low Level HBsAg
Not yet recruiting·HHuashan Hospital·Phase 4·NCT06900166·360 enrolled
Oestrogen Withdrawal in Hypopituitary Women
Completed·UUniversity of Aarhus·N/A·NCT00572390·38 enrolled
A Study to Evaluate Withdrawal Effects Following Dosing of Oxycodone/Naltrexone in Methadone-Maintained Subjects
Completed·EElite Laboratories, Inc·Phase 3·NCT02391571·26 enrolled
Activity Monitoring Assessment of Opiate Withdrawal - 4
Completed·National Institute on Drug Abuse (NIDA)·Phase 2·NCT00000335
A Dietary Supplement for Early Cigarette Withdrawal
Completed·CCentre for Addiction and Mental Health·Phase 2·NCT02042521·21 enrolled
Evaluation of Lofexidine for Treatment of Opiate Withdrawal - 10
Completed·National Institute on Drug Abuse (NIDA)·Phase 1·NCT00000345
β-blockers Withdrawal in Patients With HFpEF and Chronotropic Incompetence: Effect on Functional Capacity (Preserve-HR)
Completed·FFundación para la Investigación del Hospital Clínico de Valencia·Phase 4·NCT03871803·52 enrolled
Study of Myfortic in Combination With Tacrolimus and Thymoglobulin in Early Corticosteroid Withdrawal
Completed·UUniversity of Cincinnati·Phase 4·NCT00374803·45 enrolled
Antagonist-Elicited Cannabis Withdrawal
Completed·National Institute on Drug Abuse (NIDA)·Phase 1·NCT01041170
Systematic Withdrawal of Neurohumoral Blocker Therapy in Optimally Responding CRT Patients
Completed·HHasselt University·Phase 4·NCT02200822·80 enrolled
Treatment for Cannabis Withdrawal and Dependence
Completed·TThe Scripps Research Institute·Phase 2·NCT01611948·70 enrolled
Nicotine Patch for Marijuana Withdrawal
Completed·SSouthern Illinois University Carbondale·Phase 4·NCT01400243·127 enrolled
Page 1 of 5

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)